Future studies with a larger sample size of carriers of the C9orf72 expansions will prove useful in validating the current findings and further differentiating C9orf72 positive versus negative cases across the whole ALS–FTD spectrum. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.